About Stapokibart About Stapokibart Stapokibart is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), and is the first domestically manufactured IL-4Rα ...

Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...

Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Cullinan Therapeutics in a report released ...

Officials from China and Cuba have inaugurated the first phase of a Sino-Cuban biopharmaceutical company in Changzhi, which ...

Tonix Pharmaceuticals (NASDAQ: TNXP) released selected preliminary financial results for 2024, reporting approximately $98.8 million in cash and cas ...

The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...